Summary
Pfizer Inc. (PFE) reported a significant decrease in revenue for the second quarter and first six months of 2023 compared to the prior year, primarily driven by lower sales of its COVID-19 products, Comirnaty and Paxlovid. Total revenues for the second quarter were $12.7 billion, down 54% year-over-year, while the six-month revenue was $31.0 billion, a 42% decrease. Excluding these COVID-19 products, Pfizer saw operational revenue growth of 5% in both periods, fueled by recently acquired products and strong performance in its Vyndaqel family. The company's strategic focus is shifting, as evidenced by the pending acquisition of Seagen, a move to bolster its oncology portfolio. Despite the top-line decline due to the expected phasing out of COVID-19 related sales, Pfizer's underlying business demonstrates resilience with growth in key non-COVID-19 products. The company is actively managing its portfolio and investing in R&D, with a significant upcoming event being the proposed acquisition of Seagen, which is expected to be financed through a combination of debt and existing cash. Investors should monitor the integration of acquired assets and the impact of ongoing patent expirations on future revenue streams.
Financial Highlights
55 data points| Revenue | $13.01B |
| Cost of Revenue | $3.24B |
| Gross Profit | $9.77B |
| SG&A Expenses | $3.50B |
| Interest Expense | $508.00M |
| Net Income | $2.33B |
| EPS (Basic) | $0.41 |
| EPS (Diluted) | $0.41 |
| Shares Outstanding (Basic) | 5.65B |
| Shares Outstanding (Diluted) | 5.71B |
Key Highlights
- 1Total revenues decreased significantly by 54% to $12.7 billion for Q2 2023 and by 42% to $31.0 billion for the first six months of 2023, primarily due to a decline in COVID-19 product sales (Comirnaty and Paxlovid).
- 2Excluding COVID-19 products, operational revenue grew by 5% for both Q2 and the first six months of 2023, driven by strong performance in the Vyndaqel family, newly acquired products like Nurtec ODT/Vydura and Oxbryta, and growth in Eliquis.
- 3The company is progressing with the proposed $43 billion acquisition of Seagen, a cancer-focused biotechnology company, expected to close in late 2023 or early 2024, financed primarily by $31 billion in long-term debt issued in May 2023.
- 4Selling, informational, and administrative expenses increased by 15% in Q2 2023 and 23% for the first six months, largely due to investments in marketing for new products and preparations for the anticipated commercial launch of Paxlovid.
- 5Research and development expenses decreased slightly by 6% in Q2 2023 but increased by 1% for the first six months, reflecting ongoing investments in vaccine programs and newly acquired assets, partially offset by reduced spending on COVID-19 related R&D.
- 6Net income attributable to Pfizer Inc. common shareholders decreased substantially to $2.3 billion ($0.41 per diluted share) in Q2 2023 from $9.9 billion ($1.73 per diluted share) in Q2 2022, and to $7.9 billion ($1.38 per diluted share) for the first six months from $17.8 billion ($3.10 per diluted share) in the prior year.
- 7Pfizer experienced a significant increase in long-term debt, with $31 billion issued in May 2023 to finance the Seagen acquisition, leading to a total long-term debt of $61.4 billion as of July 2, 2023.